RE: punt27 May 2019 18:38
Mani,
I won’t argue when you bought in but I’m pretty sure you have not been holding for 12 months, I remember when you and Pred both started posting here within a week or so of each other. Anyway my point is at that time we had a “failed” phase 3 and not much else, compare that to what we have now -
1. Yoda results due, with hopefully answers as to the original P3 problem.
2. Sub group of patients covering 1/3 population that can be treated regardless of Yoda.
3. Clevegen is far more advanced than it was with admittedly very early human trials showing fantastic results.
4. Partner talks for both our lead candidate drugs.
5. A higher SP and larger market cap.
So with 12 months funding, but no info on why the P3 failed and what could have been a written off Traumakine, no human feedback on Clevegen or any hope of getting partners or further substantial shareholders on board you think then was a better time to buy than now...you are not even being honest with yourself, let alone the posters on here.